Personalised medicine as a key to treatment of rare diseases
Traditional treatments based on chemical drugs do not always work for rare diseases. They often focus on treating symptoms but fail to reverse the course of the disease itself. Personalised medicine using cell and gene therapies has the potential to reverse the negative prognosis of patients with unmet medical needs for whom there is no currently available conventional treatment.
The ultimate goal is to become a role model and flagship institution in the Central and Eastern European (CEE) region, providing excellent gene and somatic cell research to create personalised ATMP Fair Medicine for the treatment of life-threatening or chronically debilitating diseases that are currently considered incurable.
Our path to achieve the vision
CREATIC is Horizon Europe Teaming for Excellence project submitted in 9/2022. Masaryk University has established a partnership with Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig University and Copenhagen University to establish R&D centre of excellence focused on Advanced therapy medicinal products (ATMP). The strategic objectives of the project aim to use a grant of €15 million for 6 years in order to create an excellent facility for ATMP R&D focused on undiagnosed untreatable rare diseases, paediatric patients with high-risk tumours, and adult cancer patients suitable for ATMP treatment. The project evaluation is expected in early 2023.
Advanced European partners
Research programmes combining STM and SSH disciplines
announcement of the European centres supported by the Horizon Europe
Strengthen and widen comprehensive ATMPs R&I expertise
The partnership with Fraunhofer IZI, ULEI, and UCPH will expand the current MU cell-based ATMP R&D to beyond the state-of-the-art R&I&D of cell and gene therapies. A central vision of CREATIC is to deliver the research results to patients. Such ambitious goals will be implemented through 7 research programmes, combining STM and SSH disciplines
Build a role model institution
Managing the institution effectively and ensuring the capacity for long-term economic and operational sustainability requires conditions consistent with the highest international standards. We will draw on best practice and know-how from our partners Fraunhofer IZI, University of Leipzig, Copenhagen University. We have designed an autonomous management structure and research management services for the Centre under the umbrella of the Masaryk University Faculty of Medicine which will create the conditions for a continuous growth of the Centre's scientific excellence and its benefits for European citizens.
Create an ecosystem to foster pathways to deliver ATMPs to patients
To ensure the exploitation of the CREATIC results and co-creation of the specifications for the research activities, we will coordinate the ecosystem of collaborating institutions and bodies on regional, CEE, and EU levels. Through a series of inclusive and responsive stakeholder engagement activities we will obtain real-world data which will help to better understand the real and perceived challenges and opportunities for an effective implementation of ATMP innovations. The empirical data will provide an informed basis for designing, developing and implementing infrastructures which will support the innovation ecosystem responsive to stakeholder interests and concerns. This will foster greater trust, accountability, accessibility, and effective adoption of ATMP innovations.